Qrativ, a joint venture of Mayo Clinic and Nference, seeks new treatments for rare diseases by coupling Mayo research with publicly available genomic data sets.
In Science this week: fruit fly mothers pass on epigenetic information, and more.
The two firms are offering a combined genetic disease risk and pharmacogenomic analysis that covers 49 conditions and about 220 medications.
Precision medicine platform developer 2bPrecise, a subsidiary of Allscripts, will develop and test genomics care protocols with Mayo Clinic.
Pharmacogenomics informatics company OneOme will interpret and package data for Right 10K, a population-based PGx study in the US spearheaded by Mayo Clinic anf Baylor.
The Mayo Medical Laboratories laboratory is offering mate-pair sequencing for cancer and inherited disease indications, with plans to expand the service.
Biotech and academic leaders met with Trump administration officials to discuss NIH funding, ScienceInsider reports.
Building off a study that includes preemptive PGx test results in patients' EMRs, researchers want to make that information portable via a scannable card.
Grail plans to enroll up to 120,000 women who have been screened via mammogram, to train and validate its NGS-based early detection cancer test.
Specialized single-cell "cores" are popping up to help scientists get the most out of new technologies.
A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.
Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.